Skip to main content

Table 1 Clinical trials of CD47/SIRPα-targeted agents in hematological malignancies

From: Targeting macrophages in hematological malignancies: recent advances and future directions

  Type of mAb Subclass of IgG Initial time of clinical studies Phase Type of tumors Treatment programs ClinicalTrials.gov Identifier
Hu5F9-G4 mAb IgG4 2014.8 Phase II MDS and AML Combined therapy NCT02216409
Hu5F9-G4 mAb IgG4 2020.9 Phase III Higher-risk MDS Combined therapy NCT04313881
Hu5F9-G4 mAb IgG4 2021.11 Phase II R/R cHL Combined therapy NCT04788043
Hu5F9-G4 mAb IgG4 2021.12 Phase I R/R B-Malignancies Combined therapy NCT04599634
Hu5F9-G4 mAb IgG4 2022.05 Phage III TP53 Mutant AML Combined therapy NCT04778397
Hu5F9-G4 mAb IgG4 2022.9 Phase IB/II MDS and AML Combined therapy NCT05367401
TTI-621 SIRPα fusion protein IgG1 2016.1 Phase IA/IB Hematological Malignancies Monotherapy NCT02663518
TTI-621 SIRPα fusion protein IgG1 2021.10 Phase IB MM Combined therapy NCT05139225
TTI-622 SIRPα fusion protein IgG4 2018.5 Phase IA/IB Hematological Malignancies Combined therapy NCT03530683
TTI-622 SIRPα fusion protein IgG4 2021.1 Phase IB R/R MM Combined therapy NCT05139225
ALX148 IRPα fusion protein IgG1 2017.2 Phase I Lymphoma Combined therapy NCT03013218
ALX148 SIRPα fusion protein IgG1 2020.1 Phase I/II MDS Combined therapy NCT04417517
ALX148 SIRPα fusion protein IgG1 2021.1 Phase I/II B-NHL Combined therapy NCT05025800
ALX148 SIRPα fusion protein IgG1 2021.5 Phase I/II AML Combined therapy NCT04755244
AK117 mAb IgG4 2020.4 Phase I Lymphoma Monotherapy NCT04349969
AK117 mAb IgG4 2021.1 Phase I Lymphoma Monotherapy NCT04728334
AK117 mAb IgG4 2021.5 Phase I/II Higher-risk MDS Combined therapy NCT04900350
AK117 mAb IgG4 2021.7 Phase IB/II AML Combined therapy NCT04980885
Gentulizumab mAb Un 2021.4 Phase I NHL Combined therapy NCT05221385
Gentulizumab mAb Un 2021.4 Phase I R/R-AML or MDS Monotherapy NCT05263271
IMM-01 SIRPα fusion protein IgG1 2019.9 Phase I Lymphoma Monotherapy ChiCTR1900024904
IMM-01 SIRPα fusion protein IgG1 2022.1 Phase I/II MDS and AML Combined therapy NCT05140811
SRF231 mAb IgG4 2018.3 Phase IA/IB lymphoma/CLL Combined therapy NCT03512340
SHR1603 mAb IgG4 2018.1 Phase I Lymphoma Combined therapy NCT03722186
IBI188 mAb IgG4 2018.12 Phase I lymphoma Combined therapy NCT03717103
IBI188 mAb IgG4 2020.8 Phase IB Newly Diagnosed HR-MDS Combined therapy NCT04511975
IBI188 mAb IgG4 2020.9 Phase IB AML Combined therapy NCT04485052
IBI188 mAb IgG4 2020.9 Phase IB Newly Diagnosed HR-MDS Combined therapy NCT04485065
TJC4 mAb IgG4 2019.5 Phase I lymphoma Combined therapy NCT03934814
TJC4 mAb IgG4 2021.6 Phase IB MDS and AML Combined therapy NCT04912063
TJC4 mAb IgG4 2022.1 Phase IB Multiple Myeloma Combined therapy NCT04895410
ZL-1201 mAb IgG4 2020.5 Phase I Lymphoma Combined therapy NCT04257617
IMC-002 mAb IgG4 2020.6 Phase I Lymphoma Combined therapy NCT04306224
AO-176 mAb IgG2 2020.11 Phase I/II Multiple Myeloma Combined therapy NCT04445701
CC-95251 mAb IgG4 2019.2 Phase I Hematological Cancers Combined therapy NCT03783403
CC-95251 mAb IgG4 2022.1 Phase I MDS and AML Combined therapy NCT05168202
CD47 mAb Un 2021.12 Single-arm Recurrent AML After Transplantation Combined therapy NCT05266274
  1. Un Unknown